Goldfinch

Developer of precision therapies for the treatment of genetic kidney disease

placeCambridge, Massachusetts, United States calendar_todayFounded 2016 groups68 employees language goldfinchbio.com

Registered entities

Investor mix

10 investors on record; lead investors include Eventide Funds, Third Rock Ventures.

Investor typeCountShare
Venture capital440%
Private equity110%
Other / undisclosed550%
Coming soon